BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 21111321)

  • 21. Intracameral Vigamox (moxifloxacin 0.5%) is non-toxic and effective in preventing endophthalmitis in a rabbit model.
    Kowalski RP; Romanowski EG; Mah FS; Yates KA; Gordon YJ
    Am J Ophthalmol; 2005 Sep; 140(3):497-504. PubMed ID: 16083841
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of experimental bacterial keratitis with topical trovafloxacin.
    Barequet IS; Denton P; Osterhout GJ; Tuli S; O'Brien TP
    Arch Ophthalmol; 2004 Jan; 122(1):65-9. PubMed ID: 14718297
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibiotic Resistance in the Treatment of Staphylococcus aureus Keratitis: a 20-Year Review.
    Chang VS; Dhaliwal DK; Raju L; Kowalski RP
    Cornea; 2015 Jun; 34(6):698-703. PubMed ID: 25811722
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibiotic effects of WP-0405, a thermo-setting ofloxacin gel, on methicillin-resistant Staphylococcus aureus keratitis in rabbits.
    Fukaya Y; Kurita A; Tsuruga H; Naito A; Nakaya S; Sato M; Kamata Y; Hirata H; Kambara Y; Kurasawa N; Wada T; Toyoda Y; Shirasawa E; Ohashi Y
    J Ocul Pharmacol Ther; 2006 Aug; 22(4):258-66. PubMed ID: 16910867
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sustained anti-staphylococcal effect of lysostaphin in the rabbit aqueous humor.
    Balzli CL; McCormick CC; Caballero AR; O'Callaghan RJ
    Curr Eye Res; 2010 Jun; 35(6):480-6. PubMed ID: 20465441
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ex vivo efficacy of gemifloxacin in experimental keratitis induced by methicillin-resistant Staphylococcus aureus.
    Marino A; Blanco AR; Ginestra G; Nostro A; Bisignano G
    Int J Antimicrob Agents; 2016 Oct; 48(4):395-400. PubMed ID: 27554440
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aqueous penetration and biological activity of moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% solution in cataract surgery patients.
    Kim DH; Stark WJ; O'Brien TP; Dick JD
    Ophthalmology; 2005 Nov; 112(11):1992-6. PubMed ID: 16183125
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Penetration of topically applied gatifloxacin 0.3%, moxifloxacin 0.5%, and ciprofloxacin 0.3% into the aqueous humor.
    Solomon R; Donnenfeld ED; Perry HD; Snyder RW; Nedrud C; Stein J; Bloom A
    Ophthalmology; 2005 Mar; 112(3):466-9. PubMed ID: 15745775
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acute endophthalmitis in eyes treated prophylactically with gatifloxacin and moxifloxacin.
    Deramo VA; Lai JC; Fastenberg DM; Udell IJ
    Am J Ophthalmol; 2006 Nov; 142(5):721-5. PubMed ID: 16989762
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus keratitis in rabbits.
    Tas T; Kucukbayrak A; Hakyemez IN; Mengeloglu FZ; Simavli H; Ozyalvacli G; Erdurmus M
    Cornea; 2013 Jul; 32(7):1052-7. PubMed ID: 23665649
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantitative comparison of fluoroquinolone therapies of experimental gram-negative bacterial keratitis.
    Thibodeaux BA; Dajcs JJ; Caballero AR; Marquart ME; Girgis DO; O'Callaghan RJ
    Curr Eye Res; 2004 May; 28(5):337-42. PubMed ID: 15287370
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fourth-generation fluoroquinolone penetration into the aqueous humor in humans.
    McCulley JP; Caudle D; Aronowicz JD; Shine WE
    Ophthalmology; 2006 Jun; 113(6):955-9. PubMed ID: 16603244
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effectiveness of lysostaphin therapy for experimental coagulase-negative Staphylococcus endophthalmitis.
    McCormick CC; Dajcs JJ; Reed JM; Marquart ME; O'Callaghan RJ
    Curr Eye Res; 2006 Mar; 31(3):225-30. PubMed ID: 16531279
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Successful treatment with moxifloxacin of experimental aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus (MRSA).
    Galani L; Pefanis A; Sakka V; Iliopoulos D; Donta I; Triantafyllidi H; Skiadas I; Karayiannakos P; Giamarellou H
    Int J Antimicrob Agents; 2009 Jan; 33(1):65-9. PubMed ID: 18818055
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibacterial effects of moxifloxacin and levofloxacin simulating epithelial lining fluid concentrations against community-acquired methicillin-resistant Staphylococcus aureus.
    Lee SY; Fan HW; Sutherland C; DeRyke AC; Nicolau DP
    Drugs R D; 2007; 8(2):69-77. PubMed ID: 17324004
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness of fluoroquinolones against Mycobacterium abscessus in vivo.
    Caballero AR; Marquart ME; O'Callaghan RJ; Thibodeaux BA; Johnston KH; Dajcs JJ
    Curr Eye Res; 2006 Jan; 31(1):23-9. PubMed ID: 16421016
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Methicillin-resistant Staphylococcus aureus caruncle abscess.
    Koo L; Chang EL
    Ophthalmic Plast Reconstr Surg; 2007; 23(2):160-1. PubMed ID: 17413640
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antimicrobial efficacy of prophylactic gatifloxacin 0.3% and moxifloxacin 0.5% in patients undergoing phacoemulsification surgery.
    Bucci FA; Amico LM; Evans RE
    Eye Contact Lens; 2008 Jan; 34(1):39-42. PubMed ID: 18180682
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ocular pharmacokinetics, safety and efficacy of intracameral moxifloxacin 0.5% solution in a rabbit model.
    Asena L; Akova YA; Goktaş MT; Bozkurt A; Yaşar U; Karabay G; Demiralay E
    Curr Eye Res; 2013 Apr; 38(4):472-9. PubMed ID: 23373761
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Moxifloxacin efficacy and vitreous penetration in a rabbit model of Staphylococcus aureus endophthalmitis and effect on gene expression of leucotoxins and virulence regulator factors.
    Bronner S; Jehl F; Peter JD; Ploy MC; Renault C; Arvis P; Monteil H; Prevost G
    Antimicrob Agents Chemother; 2003 May; 47(5):1621-9. PubMed ID: 12709331
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.